Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Viibryd (vilazodone hydrochloride) is indicated for the treatment of major depressive disorder (MDD) in adults.
• This summary is based on the review of three systematic review(s)/meta-analysis(es). ^[1-3]
• Vilazodone vs. Placebo in MDD: Vilazodone was significantly superior to placebo in treating Major Depressive Disorder (MDD), though it is not recommended as a first-line treatment due to unclear advantages over existing treatments.
• Comparative Effectiveness: Other antidepressants such as desvenlafaxine, paroxetine, venlafaxine, and vortioxetine were noted for reasonable efficacy, acceptability, and tolerability, but there was no specific data on vilazodone's performance relative to these antidepressants in terms of relapse rates or overall effectiveness.
• Population Considerations: There were no specific effectiveness outcomes reported for different population types or subgroups in the studies provided.
• Safety Outcomes: Vilazodone was associated with severe toxicity, including serotonin syndrome and seizures, particularly in children, even at minimal doses, with frequent ICU admissions and intensive care interventions required. Specific adverse events for vilazodone were not detailed in other safety outcomes.
• Comparative Safety: Vilazodone may cause more frequent serotonin syndrome in single-substance ingestions compared to SSRIs, with a high risk of severe clinical toxicity noted in children.
• Children: High risk of severe toxicity, including serotonin syndrome and seizures, even with minimal doses of vilazodone.
• Adults and Adolescents: Risk of serotonin syndrome after single-substance ingestion of vilazodone, necessitating careful monitoring.
• General Population: Need for more phase IV studies to establish the efficacy and long-term safety of vilazodone in larger and more diverse populations.